NCT06414902Not yet recruiting
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer CenterPhase 1ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Esophageal Cancer
- Drug/Device/Intervention
- ArabinoFuranosylGuanine [18F]F-AraG
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- M.D. Anderson Cancer Center
- Location
- Houston, United States of America
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Nov 29, 2024
- End date
- Oct 01, 2027
- Enrollment
- 60 participants
Primary outcome
Safety and adverse events (AEs)
Summary
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and
 predict a participant's response to treatment.
ICD-10 classifications
Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06414902
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06414902 through Pure Global AI's free database. This Phase 1 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Esophageal Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.